2018 International Congress

October 5-9, 2018. Hong Kong. Abstracts are presented on the 6th, 7th, and 8th.

View by Title View Sessions

View by Date

Saturday, October 6, 2018

1:45pm-3:15pm: The effects of Nordic walking on gait functions in people with Parkinson’s disease: A long-term pilot study

M. Mak, I. Wong-Yu (Hong Kong, Hong Kong)

Clinical Trials and Therapy in Movement Disorders · Hall 3FG

1:45pm-3:15pm: The effects of STN-DBS on the Parkinson’s disease patients with different progressive rates

R. Qi, H. Yu, J. Li, X. Geng (Kunming, China)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: The effects of treadmill training augmented by virtual reality on postural control and freezing of gait in Parkinson’s disease

E. Bekkers, A. Mirelman, S. Del Din, L. Avanzino, F. Nieuwhof, J. Hausdorff, A. Nieuwboer (Leuven, Belgium)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: The efficacy and safety of STN-DBS under general anesthesia for PD patients

W. Chen, L. Chen (Guangzhou, China)

Surgical Therapy: Parkinson's Disease · Hall 3FG

1:45pm-3:15pm: The efficacy of intensive inpatient rehabilitation treatment in Parkinson’s disease patients

J. Shiraishi, T. Okazaki, S. Saeki (Fukuoka, Japan)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: The establishment of Deep Brain Stimulation Nurse Association (DBSNA) in United Kingdom (UK)

J. Candelario-Mckeown, L. Partington-Smith, U. Brechany, L. Mooney-Messer, J. Kausar, B. Forrow, S. Perides, L. Nelson (London, United Kingdom)

Education in Movement Disorders · Hall 3FG

1:45pm-3:15pm: The first case of Perry syndrome in Estonia

K. Vender, T. Toomsoo, I. Kalju, I. Rubanovits, K. Joost, P. Taba (Tallinn, Estonia)

Rare Genetic and Metabolic Diseases · Hall 3FG

1:45pm-3:15pm: The FOsmetpantotenate Replacement Therapy (FORT) Pivotal Trial: Utilization of a Novel Primary Efficacy Outcome in Patients with Pantothenate Kinase-Associated Neurodegeneration

F. Greblikas, M. Escolar, T. Klopstock, R. Marshall, B. Perez, S. Tuller, A. Videnovic (San Diego, CA, USA)

Clinical Trials and Therapy in Movement Disorders · Hall 3FG

1:45pm-3:15pm: The highly selective 5-HT2A receptor antagonist EMD-281,014 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease

I. Frouni, D. Bedard, S. Belliveau, E. Bourgeois-Cayer, A. Hamadjida, P. Huot (Montreal, QC, Canada)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: The History of Huntington Disease Description in Russia

D. Labunskiy (Santa Rosa, CA, USA)

History · Hall 3FG